Anti-Mouse LPAM-1- Purified in vivo PLATINUM™ Functional Grade

TK1 cells

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

B This antibody has been reported to block α4β7 mediated lymphocyte adhesion to VCAM-1, MAdCAM-1, and fibronectin for In vitro and In vivo studies.
IHC FF
IP

Clone DATK32 recognizes an epitope specific to the mouse LPAM-1 heterodimer.

LPAM-1 antibody, clone DATK32, recognizes mouse lymphocyte Peyer’s patch adhesion molecule (LPAM-1), also known as integrin alpha 4 beta 7 (α4β7). LPAM-1 is a heterodimer of the 154 kDa integrin α4 (CD49d) and 130 kDa integrin β7 chains and is a member of the Ig superfamily. LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow hematopoietic stem cells^1,2. LPAM-1 mediates adhesion to endothelial cells, promoting leukocyte transmigration across high endothelial venules (HEVs) during the inflammatory response. LPAM-1 binds to several ligands, including vascular adhesion molecule-1 (VCAM-1/CD106), mucosal addressin cell adhesion molecule-1 (MAdCAM-1), and fibronectin. MAdCAM-1 is expressed exclusively on endothelial cells of the gut and gut-associated lymphoid tissues, such as Peyer’s patches (PPs), and binding of LPAM-1 to MAdCAM-1 contributes to lymphocyte homing to mucosal tissues^3,4. Vedolizumab, an anti-LPAM-1 monoclonal antibody, is approved to treat inflammatory bowel disease and effectively induces and maintains remission in Crohn's disease and ulcerative colitis^5-8.

LPAM-1 is expressed on most peripheral lymphocytes, subsets of thymocytes, and bone marrow progenitor cells.

VCAM-1 (CD106), MAdCAM-1, fibronectin

Lymphocyte adhesion

1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905
2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26
3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8
4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93
5. Sandborn WJ, et al. (2013) N Engl J Med. 369:711–721
6. Feagan BG, et al. (2013) N Engl J Med. 369:699–710
7. Kopylov U, et al. (2019) Dig Liver Dis. 51:68–74
8. Danese S, et al. (2019) Gastroenterology.157:1007–1018 e1007